WO2006133135A3 - Herpes virus-based compositions and methods of use - Google Patents

Herpes virus-based compositions and methods of use Download PDF

Info

Publication number
WO2006133135A3
WO2006133135A3 PCT/US2006/021824 US2006021824W WO2006133135A3 WO 2006133135 A3 WO2006133135 A3 WO 2006133135A3 US 2006021824 W US2006021824 W US 2006021824W WO 2006133135 A3 WO2006133135 A3 WO 2006133135A3
Authority
WO
WIPO (PCT)
Prior art keywords
herpes virus
methods
based compositions
virus particles
chromosomes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/021824
Other languages
French (fr)
Other versions
WO2006133135A2 (en
Inventor
Howard J Federoff
William J Bowers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Rochester
Original Assignee
University of Rochester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Rochester filed Critical University of Rochester
Priority to AU2006255167A priority Critical patent/AU2006255167A1/en
Priority to US11/916,440 priority patent/US20080193416A1/en
Priority to CA002615638A priority patent/CA2615638A1/en
Priority to EP06784591A priority patent/EP1904112A2/en
Publication of WO2006133135A2 publication Critical patent/WO2006133135A2/en
Anticipated expiration legal-status Critical
Publication of WO2006133135A3 publication Critical patent/WO2006133135A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56994—Herpetoviridae, e.g. cytomegalovirus, Epstein-Barr virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10311—Siphoviridae
    • C12N2795/10361—Methods of inactivation or attenuation
    • C12N2795/10362—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/20—Pseudochromosomes, minichrosomosomes
    • C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/90—Vectors containing a transposable element
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2820/00—Vectors comprising a special origin of replication system
    • C12N2820/10—Vectors comprising a special origin of replication system multiple origins of replication
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2820/00—Vectors comprising a special origin of replication system
    • C12N2820/55—Vectors comprising a special origin of replication system from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2820/00—Vectors comprising a special origin of replication system
    • C12N2820/60—Vectors comprising a special origin of replication system from viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/03—Herpetoviridae, e.g. pseudorabies virus
    • G01N2333/035—Herpes simplex virus I or II

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

This disclosure features vectors, targeting vectors, modified artificial chromosomes, herpes virus particles in which such chromosomes are packaged, and methods of using the herpes virus particles to identify therapeutic agents and targets for therapeutic intervention.
PCT/US2006/021824 2005-06-03 2006-06-05 Herpes virus-based compositions and methods of use Ceased WO2006133135A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2006255167A AU2006255167A1 (en) 2005-06-03 2006-06-05 Herpes virus-based compositions and methods of use
US11/916,440 US20080193416A1 (en) 2005-06-03 2006-06-05 Herpes Virus-Based Compositions and Methods of Use
CA002615638A CA2615638A1 (en) 2005-06-03 2006-06-05 Herpes virus-based compositions and methods of use
EP06784591A EP1904112A2 (en) 2005-06-03 2006-06-05 Herpes virus-based compositions and methods of use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68736005P 2005-06-03 2005-06-03
US60/687,360 2005-06-03

Publications (2)

Publication Number Publication Date
WO2006133135A2 WO2006133135A2 (en) 2006-12-14
WO2006133135A3 true WO2006133135A3 (en) 2008-08-14

Family

ID=37499027

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/021824 Ceased WO2006133135A2 (en) 2005-06-03 2006-06-05 Herpes virus-based compositions and methods of use

Country Status (5)

Country Link
US (1) US20080193416A1 (en)
EP (1) EP1904112A2 (en)
AU (1) AU2006255167A1 (en)
CA (1) CA2615638A1 (en)
WO (1) WO2006133135A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8324367B2 (en) * 2006-11-03 2012-12-04 Medtronic, Inc. Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1263159A (en) * 1999-10-27 2000-08-16 北京东康龙病毒生物技术工程研究中心 New type simple herpesvirus amplicon carrier system and its application
WO2002053576A1 (en) * 2001-01-05 2002-07-11 The General Hospital Corporation Viral delivery system for infectious transfer of large genomic dna inserts

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0448650A4 (en) * 1989-02-01 1992-05-13 The General Hospital Corporation Herpes simplex virus type i expression vector
DE69328514T2 (en) * 1992-03-13 2001-01-11 Monsanto Co., St. Louis Production of recombinant proteins using herpes virus promoters and VP16 transactivators
WO1994004695A1 (en) * 1992-08-14 1994-03-03 The Rockefeller University Herpesviral defective vector with rat preproenkephalin gene promoter
US5661033A (en) * 1992-11-25 1997-08-26 The Board Of Trustees Of The Leland Stanford Junior University Gene transfer using herpes virus vectors as a tool for neuroprotection
US5763217A (en) * 1993-11-10 1998-06-09 University Of British Columbia Method of using, process of preparing and composition comprising recombinant herpesvirus vectors
CA2215162A1 (en) * 1995-03-23 1996-09-26 Cantab Pharmaceuticals Research Limited Vectors for gene delivery
US5851826A (en) * 1995-07-26 1998-12-22 Children's Medical Center Corporation Helper virus-free herpesvirus vector packaging system
US6344445B1 (en) * 1995-10-19 2002-02-05 Cantab Pharmaceutical Research Limited Herpes virus vectors and their uses
US5965441A (en) * 1996-11-13 1999-10-12 The General Hospital Coporation HSV/AAV hybrid amplicon vectors
US6051428A (en) * 1997-03-21 2000-04-18 Sloan-Kettering Institute For Cancer Research Rapid production of autologous tumor vaccines
EP0915165B1 (en) * 1997-11-05 2003-02-19 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Method for the helper virus-free packaging of a DNA-vector
WO2001030965A2 (en) * 1999-10-28 2001-05-03 The Board Of Trustees Of The Leland Stanford Junior University Methods of in vivo gene transfer using a sleeping beauty transposon system

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1263159A (en) * 1999-10-27 2000-08-16 北京东康龙病毒生物技术工程研究中心 New type simple herpesvirus amplicon carrier system and its application
WO2002053576A1 (en) * 2001-01-05 2002-07-11 The General Hospital Corporation Viral delivery system for infectious transfer of large genomic dna inserts

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
LAUTH M.: "Stable and efficient cassette exchange under non-selectable conditions by combined use of two site-specific recombinases", NUCLEIC ACIDS RES., vol. 30, no. 21, E115, November 2002 (2002-11-01), pages 1 - 7, XP002332394 *
SAEKI Y. ET AL.: "Herpes simplex virus type 1 DNA amplified as bacterial artificial chromosome in Escherichia coli: rescue of replication-competent virus progency and packaging of amplicon vectors", HUMAN GENE THERAPY, vol. 9, no. 18, December 1998 (1998-12-01), pages 2787 - 2794, XP000915427 *
WADE-MARTINS R.: "An infectious and expression system for genomic DNA loci in human and mouse cells", NATURE BIOTECHNOLOGY, vol. 19, no. 11, November 2002 (2002-11-01), pages 1067 - 1070 *
WADE-MARTINS R.: "Infectious delivery of a 135-kb LDLR genome locus leads to regulated complementation of low-density lipoprotein receptor deficiency in human cells", MOL. THER., vol. 5, no. 1, May 2003 (2003-05-01), pages 604 - 612 *
XING W.: "HSV-1 amplicon-mediated transfer of 128-kb BMP-2 genomic locus stimulates osteoblast differentiation in vitro", BIOCHEM. BIOPHYS. RES. COMMUN., vol. 319, no. 3, July 2004 (2004-07-01), pages 781 - 786, XP004512507 *

Also Published As

Publication number Publication date
WO2006133135A2 (en) 2006-12-14
AU2006255167A1 (en) 2006-12-14
EP1904112A2 (en) 2008-04-02
CA2615638A1 (en) 2006-12-14
US20080193416A1 (en) 2008-08-14

Similar Documents

Publication Publication Date Title
AU2018236742B2 (en) Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
WO2019126762A3 (en) Cas12a systems, methods, and compositions for targeted rna base editing
WO2008133663A3 (en) Codon modified immunogenic compositions and methods of use
WO2007067681A3 (en) Immunostimulatory compositions and methods
EP4435007A3 (en) Trispecific proteins and methods of use
WO2011141705A8 (en) Novel cationic lipids and methods of use thereof
WO2011072218A3 (en) Stable formulations for lyophilizing therapeutic particles
MY161495A (en) Virus like particle compositions and methods of use
WO2009012176A3 (en) Methods and compositions for treating brain diseases
WO2008094254A3 (en) Methods and compositions for the treatment of cancer or other diseases
WO2008103947A3 (en) Activation of human antigen-presenting cells through clec-6
SG10201405377XA (en) Compositions and methods for antibodies targeting complement protein c5
WO2010048536A3 (en) Processes for preparing lipids
WO2011160024A3 (en) Compounds useful as antiviral agents, compositions, and methods of use
WO2008061243A3 (en) Respiratory syncytial virus-virus like particle (vlps)
WO2007042554A3 (en) Methods and compositions for treating immune disorders
EA201170493A1 (en) MICROORGANISMS AND VACCINES DEPENDING ON REPLICATION OF NON-NATURAL AMINO ACIDS
WO2011130164A3 (en) Unconjugated anti-tfr antibodies and compositions thereof for the treatment of cancer
WO2008073448A3 (en) Pharmaceutical formulations and methods for making the same
WO2008106646A3 (en) Methods and formulations for topical gene therapy
ZA200803131B (en) Rabies virus vector systems and compositions and methods thereof
WO2008124646A3 (en) Use of amyloid proteins as vaccine scaffolds
WO2007092496A3 (en) 7,9-dihydro-purin-8-one and related analogs as hsp90-inhibitors
GB0508110D0 (en) Gene delivery
WO2012010974A3 (en) Combination pharmaceutical compositions and method of treatment of vertigo, kinetosis and vegetative-vascular dystonia

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006784591

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006255167

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2615638

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2006255167

Country of ref document: AU

Date of ref document: 20060605

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 11916440

Country of ref document: US